{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:55:30Z","timestamp":1791975330633,"version":"4.4.0"},"reference-count":0,"publisher":"Knowledge E DMCC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJHOSCR"],"abstract":"<jats:p>Background: Acute-phase reactant proteins, particularly C-reactive protein (CRP), play a critical role in the initiation, progression, and recurrence of cancers such as acute myeloid leukemia.\r\nMaterials and Methods: We retrospectively analyzed 127 newly diagnosed non-M3 acute myeloblastic leukemia (non-M3 AML) patients. We investigated pre-treatment levels of C-reactive protein (CRP), Albumin, and C-reactive protein to albumin ratio (CAR) with cytogenetics, response to induction therapy, recurrence, and overall survival.\r\nResults: We did not find any relationship between levels of CRP, Albumin, and C-reactive protein to albumin ratio (CAR) with complete remission rate, recurrence, and risk categorization of patients (P &gt; 0.05). 3-and 5- year overall survival was 40.8% (with a standard error of 4.7%) and 30.1% (standard error: 5.3%), respectively. In addition, 3-year and 5-year event-free survival was 31.3% (standard error = 4.4%) and 25.8% (standard error = 4.8%), respectively. The only prognostic factor was allogenic stem cell transplantation (SCT).\r\nConclusion: Although CRP, Albumin, and CAR serve as convenient prognostic markers, they were not predictive of overall survival (OS) and event-free survival (EFS) in AML patients. Further studies are needed in the future to confirm or refute our results.<\/jats:p>","DOI":"10.18502\/ijhoscr.v19i2.18547","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T07:16:18Z","timestamp":1746256578000},"source":"Crossref","is-referenced-by-count":1,"title":["The Prognostic Value of C-Reactive Protein and Albumin in Newly Diagnosed Patients with AML"],"prefix":"10.18502","author":[{"given":"Nasrin","family":"Namdari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sezaneh","family":"Haghpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe","family":"Ataie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateme","family":"Ghanbarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahya","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7770","published-online":{"date-parts":[[2025,5,3]]},"container-title":["International Journal of Hematology-Oncology and Stem Cell Research"],"original-title":[],"link":[{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/IJHOSCR\/article\/download\/18547\/17272","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/IJHOSCR\/article\/download\/18547\/17272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:26:46Z","timestamp":1772105206000},"score":1,"resource":{"primary":{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/IJHOSCR\/article\/view\/18547"},"secondary":[{"URL":"https:\/\/ijhoscr.tums.ac.ir\/index.php\/ijhoscr\/article\/view\/2315","label":"UNIVERSITY"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":0,"URL":"https:\/\/doi.org\/10.18502\/ijhoscr.v19i2.18547","relation":{},"ISSN":["2008-2207"],"issn-type":[{"value":"2008-2207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,3]]}}}